Barclays PLC Ligand Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 10, 2020	SELL	$96.94 - $113.59 $87,246 - $102,231	-900 Reduced 90.0%	100 $10,000
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $86,250 - $120,160	-1,000 Reduced 50.0%	1,000 $100,000
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $107,380 - $129,340	1,000 Added 100.0%	2,000 $228,000
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $74,151 - $99,729	700 Added 233.33%	1,000 $126,000
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $25,672 - $54,426	200 Added 200.0%	300 $41,000
Q2 2018 Aug 14, 2018	SELL	$150.77 - $207.98 $75,385 - $103,990	-500 Reduced 83.33%	100 $21,000
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $55,452 - $73,048	400 Added 200.0%	600 $99,000
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $24,182 - $27,588	200	200 $27,000

262

18M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.98B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.